Drug Profile
GSK 2190914
Alternative Names: 2190914; AM103; GSK-2190914Latest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator Amira Pharmaceuticals
- Developer Amira Pharmaceuticals; GlaxoSmithKline
- Class Antiasthmatics
- Mechanism of Action 5-lipoxygenase activating protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma; Cardiovascular disorders
Most Recent Events
- 14 Oct 2014 Discontinued - Phase-I for Cardiovascular disorders in Europe (PO)
- 14 Oct 2014 Discontinued - Phase-II for Asthma in Europe (PO)
- 07 Sep 2011 Amira Pharmaceuticals has been acquired by Bristol-Myers Squibb